In recent years, biotech companies such as Genentech have made efforts in developing potential monoclonal antibodies against the ligand for PD-1, PD-L1, as another mechanism to activate T cell-mediated immune responses and inhibit the immune-suppressive mechanisms of PD-1 in certain cancers [39]. Here, PDCD1 is linked to cancer.